🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Fennec Pharmaceuticals Inc. FENC R2KPHARMA

Healthcare · Biotechnology · United States
https://www.fennecpharma.com
Company Profile ↓
$12.39
+36.00% 1Y
Mkt Cap$430.39M
P/E-42.72
P/B10.61
52W High$12.78
52W Low$5.77
Book Value$1.09
EPS (TTM)$-0.29

Company Overview

Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Recent Developments

  • Dec 2025 Revenue of $44.64M (-6.1% YoY); net profit $-9.74M.
  • Trailing 12 Months Year-on-year growth — revenue +72.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-
1 Year:72.60%

Stock Price Performance

1 Year:+36.00%
6 Months:+60.91%
3 Months:+42.41%
1 Month:+14.30%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 94% of range
$5.77 $12.78
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)59.51 · Neutral
Price Performance
1M+14.30%
3M+42.41%
6M+60.91%
1Y+36.00%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-42.72
Industry PE
25.17
Forward P/E
13.92
PEG Ratio
1.47
Book Value
$1.09
Price to Book
10.61
P/S
7.88
EV/EBITDA
-61.27
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-
Profit 5Y
-
Revenue (YoY)
72.60%
Earnings (YoY)
-

Profitability & Returns

ROCE
-10.46%
ROE
-52.68%
ROA
-5.91%
Profit Margin
-16.42%
Op Margin
-0.79%
Gross Margin
92.23%
EPS (Latest Qtr)
$0.01
EPS (TTM)
$-0.29

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
6.15
Current Ratio
6.98
Debt
$0
Total Assets
$71.82M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
14.31%
Chg in Prom Hold
-0.14%
FII / Inst Holding
54.32%
Chg in FII Hold
0.00%

Financial Snapshot

Enterprise Value
$430.39M
Total Revenue (TTM)
$51.00M
EBITDA
$-5.49M
Free Cash Flow
$-2.37M
Operating Cash Flow
$-5.78M
Shares Outstanding
34.74M
Gross Margin
92.23%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 FENC Fennec Pharmaceuticals Inc. R2KPHARMA 12.39 -42.72 $430.39M 0.00% -10.46% -52.68% - -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue 0000000-000-0000000000000-----1.68M3.33M6.51M25.38M7.26M6.97M8.75M9.65M12.46M15.11M
Gross Profit ------------------------------1.58M3.18M6.18M-------
Operating Income -51.00K-537.00K-930.00K-619.00K-452.00K-549.00K-338.00K--454.00K-707.00K-564.00K--771.00K-1.48M-2.19M-1.79M-2.67M-2.85M-2.68M-4.81M-1.86M-3.83M-4.84M-5.86M-4.92M-3.92M-4.17M-3.55M-5.01M-7.90M-5.27M-4.67M-1.02M13.74M-5.04M-5.20M-808.00K-2.73M-189.00K-119.00K
Net Income -1.77M-3.19M-750.00K380.00K177.00K-173.00K-123.00K-540.00K-420.00K-724.00K-502.00K-1.14M-806.00K-1.60M-2.35M-1.57M-2.59M-2.75M-2.63M-4.73M-1.81M-3.83M-4.84M-6.20M-4.73M-4.00M-4.18M-3.70M-5.07M-8.09M-6.05M-5.44M-1.87M12.84M-5.55M-5.74M-1.17M-3.15M-638.00K201.00K
Diluted EPS --0.33-0.080.030.01-0.02-0.01--0.04-0.06-0.04--0.06-0.11-0.15-0.09-0.14-0.140.14-0.24-0.09-0.19-0.21-0.24-0.18-0.15-0.16-0.14-0.19-0.31-0.23-0.21-0.070.41-0.20-0.21-0.04-0.11-0.020.01
R&D Expense --72.00K88.00K43.00K54.00K88.00K-47.00K139.00K112.00K-225.00K333.00K492.00K689.00K798.00K1.80M1.67M1.97M795.00K1.39M1.12M1.37M2.42M800.00K1.24M1.44M1.13M846.00K4.00K8.00K12.00K3.00K157.00K97.00K94.00K107.00K29.00K49.00K

Profit & Loss (Annual)

Figures in USD.

Metric Jun 1997Jun 1998Jun 1999Jun 2000Jun 2001Jun 2002Jun 2003Jun 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue --------------000000000170.00K-1.53M21.25M47.54M44.64M
Gross Profit -------------------------1.45M19.99M--
Operating Income --------------4.60M-3.44M-3.62M-1.93M-2.88M-1.89M-2.87M-6.95M-10.41M-13.01M-17.89M-17.22M-22.59M-12.77M2.57M-6.28M
Net Income -37.00K-398.00K-958.00K-1.60M-2.52M-3.73M-17.80M-6.87M-13.87M-16.44M-13.36M-13.60M-3.01M-7.82M4.68M-5.16M1.84M-2.18M-659.00K-2.79M-7.05M-9.89M-12.78M-18.11M-17.35M-23.71M-16.05M-436.00K-9.74M
Diluted EPS --------------0.490.19-0.210.17-0.22-0.06-----0.76-0.67-0.90-0.60-0.02-0.34
R&D Expense --------------1.49M2.08M579.00K357.00K256.00K472.00K1.94M5.01M5.61M5.11M4.98M3.53M56.00K307.00K250.00K

Balance Sheet (Annual)

Figures in USD.

Metric Sep 1996Jun 1997Jun 1998Jun 1999Jun 2000Jun 2001Jun 2002Jun 2003Jun 2004Dec 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Sep 2023Dec 2023Dec 2024Dec 2025
Total Assets ---------------5.99M5.35M2.37M1.75M2.37M1.02M3.97M28.40M22.95M14.15M31.42M22.41M26.94M19.98M26.86M44.95M70.55M
Total Equity 0-37.00K-435.00K242.00K47.00K9.79M6.07M698.00K20.45M16.65M11.08M1.27M14.15M3.05M406.00K-4.92M-119.00K-4.96M-1.46M613.00K548.00K3.57M26.76M21.31M11.88M29.07M15.77M-2.57M9.58M-11.62M-5.87M35.47M
Cash & Equivalents 0-------------685.00K5.95M5.30M2.30M1.66M2.31M942.00K3.93M28.26M22.78M13.65M30.34M21.10M23.77M-13.27M26.63M36.79M
Long Term Debt ---------------------------24.90M-30.93M19.34M-
Total Liabilities ---------------10.92M5.47M7.32M3.21M1.76M471.00K402.00K1.64M1.64M2.27M2.35M6.64M29.51M-38.49M50.82M35.08M
Current Liabilities ---------------10.92M5.47M7.32M3.21M1.76M471.00K402.00K1.64M1.64M2.27M2.35M1.65M4.61M-7.55M6.92M10.52M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -1.93M-3.23M-2.99M-2.21M-1.70M-2.12M-3.64M-7.83M-9.06M-15.60M-14.22M-18.06M-17.14M26.98M-12.47M
Investing Cash Flow -0000000-------
Financing Cash Flow 7.19M2.57M01.57M2.34M5.11M27.98M2.35M-71.00K32.29M4.98M20.73M6.64M-13.62M22.63M
Capital Expenditure --0-0-0-----------
Free Cash Flow --3.23M-2.99M-2.21M-----------

Ratios (Annual)

Figures in %.

Metric Jun 1997Jun 1998Jun 1999Jun 2000Jun 2001Jun 2002Jun 2003Jun 2004Dec 2005Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------------------------94.4%94.1%--
Operating Margin % ------------------------10,520.6%--1,471.6%-60.1%5.4%-14.1%
Net Margin % ------------------------10,652.4%--1,544.9%-75.5%-0.9%-21.8%
ROE % 100.0%91.5%-395.9%-3,414.9%-25.8%-61.5%-2,549.4%-33.6%-125.2%-1,296.5%-94.4%-445.5%-741.9%158.8%-3,937.0%104.2%-126.8%-355.0%-120.3%-78.1%-26.3%-46.4%-107.6%-62.3%-110.0%923.1%138.1%7.4%-27.5%
ROCE % -------------93.5%2,865.0%73.0%132.7%-469.3%-344.9%-80.4%-26.0%-48.8%-109.5%-61.5%-83.0%-101.2%-66.1%6.8%-10.5%

Shareholding Pattern

Insiders
14.31%
Institutions
54.32%
Public Float
63.39%

Top Institutional Holders

#Holder% HeldSharesValue
1 Rosalind Advisors, Inc. 9.09% 3.19M $39.12M
2 AIGH Capital Management LLC 7.09% 2.49M $30.50M
3 Solas Capital Management, LLC 5.39% 1.89M $23.18M
4 Blackrock Inc. 4.93% 1.73M $21.19M
5 AWM Investment Company, Inc. 3.31% 1.16M $14.24M
6 Vanguard Capital Management LLC 2.39% 839.31K $10.30M
7 Prospect Capital Advisors, LLC 1.42% 497.80K $6.11M
8 State Street Corporation 1.22% 426.00K $5.23M
9 Geode Capital Management, LLC 1.15% 402.57K $4.94M
10 Jane Street Group, LLC 0.67% 233.88K $2.87M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FENC

Google News Fri, 14 Aug 2026

Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxOUWpBWVcta0M0MUhyZzZWRGFwSzhyUWhNSmI2LTF0WFhsRGlBdU4yMjFhQ2lWVXliUVdDX2dESE9kYUlMX2RYQVFlemVINkZvNWU2NTdTOXlkM1VoRjdZNU8yY1lxc2NVc0FlT283Nkh1a0pZelFpMWxMV1RJbGU1QkJOc0NNMmVBaFNrYS…

Google News Sun, 06 Sep 2026

(FENC) Risk Channels and Responsive Allocation - Stock Traders Daily

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxPa0hyM1VHS241ZlplRjBlUDlsWEl3eEUwVlVlMW9wa3FvQ0d3QV9TUVROa1lIdGJTNGg4S25xdTU3ZmRiX2VhZ2lrc1kxNHVUb3FfeDBhdW40bjdhNG92UlNISVdJWml4ejh6clpJUENiZFRzNmk1UHJybFVoWmJpeVp2eWhvanRRVGFxQT…

Google News ue, 01 Sep 2026

Former Fennec (NASDAQ: FENC) director lines up $121K stock sale - Stock Titan

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxQVWplbG83OGp4Q2NncWVaTDhfMWwzWGtXT0JLdTJMbDFLYUVXdm5INXBuWnc0MS1CT0F5Z1hSQTJoMmtCZFFTdS1rLVZ2dUhPVm9hWVAtQmR2cURoV1J5ZGZwRWR1UHdQcEtOSTdqVUgtUUtkby11NzRfNkw0TGI1N0pRcWI5ak0wUENGM2…

Google News ue, 01 Sep 2026

Insider Sale: Chief Medical Officer of $FENC Sells 12,000 Shares - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMipgFBVV95cUxNNGJIUzJudThQSGlQM3FhRHJfQjFNVF9HS3MyR2RMdUhqRlgzRHQ2X0dZc1ZvUnhVOXh2V1hvNUNlQWZGaFdDZ3hRTnpjRy1hVzJJTDdheXVMeUNvS1QwN19SRkQ5YnR3Mnpxdm1DOTQ3VzRfLUgxVXl1V1M1UWdJTFJ4cXFfeDUxTXF5OD…

Google News hu, 25 Jun 2026

FENC Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE8tOGFBM3FWdG96c2tVcWVwWnZIOE1WS0R4WktobEdLd25JZzFZYnJtQkEwNGU4T3FrMnM3dFM3ZW8weDlrMHk5a19td20wXy1pLWF3UEpyNUNYVk1OUi05cHVReXQxQ1JUZWQ4d254VldkS1RUSEE1TXJB?oc=5" target="_blank">FEN…

Google News Wed, 12 Aug 2026

Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPejAxYS0zU3BzVXd1ekV4bHpka2V0WkhiOEtzRFRjOGtidjBPT04zOGhIRW4zV2FIWFplVDJUXzNKNUVTbmF2RkdLYUYxOW95NkozcERlajFQNnlBSTNUZk9Ea0MtNGQyb21XNU13dmd4OGl5OVFyMXJxVkRyb01iaW1BY0VPZUoxNENENj…

FENC — Frequently Asked Questions

What is the current share price of Fennec Pharmaceuticals Inc. (FENC)?

As of 2026-09-07 16:24 PDT, Fennec Pharmaceuticals Inc. (FENC) trades at $12.39 on NasdaqCM. Its 52-week range is $5.77 to $12.78.

What is the market capitalisation of FENC?

Fennec Pharmaceuticals Inc. (FENC) has a market capitalisation of $430.39M on NasdaqCM.

What is the P/E ratio of FENC?

FENC trades at a trailing price-to-earnings (P/E) ratio of -42.72. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 10.61.

What is the return on equity (ROE) of FENC?

FENC has a return on equity (ROE) of -52.68%. Its return on capital employed (ROCE) is -10.46%.

Is FENC a good stock to buy?

This page provides a data-driven analysis of Fennec Pharmaceuticals Inc. (FENC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space